1 523

Cited 17 times in

Healing effects of rebamipide and omeprazole in Helicobacter pylori-positive gastric ulcer patients after eradication therapy: a randomized double-blind, multinational, multi-institutional comparative study

Authors
 Song K.H.  ;  Lee Y.C.  ;  Fan D.-M.  ;  Ge Z.-Z.  ;  Ji F.  ;  Chen M.-H.  ;  Jung H.C.  ;  Bo J.  ;  Lee S.W.  ;  Kim J.-H. 
Citation
 DIGESTION, Vol.84(3) : 221-229, 2011 
Journal Title
DIGESTION
ISSN
 0012-2823 
Issue Date
2011
MeSH
Adult ; Aged ; Aged, 80 and over ; Alanine/adverseeffects ; Alanine/analogs & derivatives* ; Alanine/therapeutic use ; Amoxicillin/therapeutic use ; Anti-Bacterial Agents/therapeutic use ; Anti-UlcerAgents/therapeutic use* ; Clarithromycin/therapeutic use ; Double-BlindMethod ; Female ; HelicobacterInfections/drugtherapy ; HelicobacterInfections/microbiology* ; Helicobacterpylori* ; Humans ; Intention to Treat Analysis ; Male ; Middle Aged ; Omeprazole/adverseeffects ; Omeprazole/therapeutic use* ; Quinolones/adverseeffects ; Quinolones/therapeutic use* ; StomachUlcer/drugtherapy* ; StomachUlcer/microbiology ; StomachUlcer/pathology ; Treatment Outcome ; WoundHealing ; Young Adult
Keywords
Gastric ulcer ; Helicobacter pylori ; Omeprazole ; Proton pump inhibitor ; Rebamipide ; Treatment efficacy
Abstract
BACKGROUND AND AIMS: A recent placebo-controlled trial showed that rebamipide, which is a mucosal-protective antiulcer agent, promoted gastric ulcer healing without affecting the Helicobacter pylori status. We conducted a randomized, double-blind trial to compare the healing effects of rebamipide and the proton-pump inhibitor omeprazole in H. pylori-positive gastric ulcers after H. pylori eradication therapy.

METHODS: After completion of 1 week of eradication therapy, 132 patients with H. pylori-positive gastric ulcer were enrolled in 5 Chinese and 4 Korean institutions. Patients were randomly assigned to take either 20 mg of omeprazole (n = 63) or 300 mg of rebamipide (n = 65) daily for 7 weeks. Healing was defined as complete recovery and S1 and S2 stage ulcer according to the Sakita-Miwa classification.

RESULTS: Healing rates at 12 weeks were 81.5% (53/65) and 82.5% (52/63) in the rebamipide and omeprazole groups, respectively. There was no significant difference in treatment efficacy, as evidenced by gastric ulcer healing rates (absolute difference -1.0%; 95% confidence interval -10.7 to 8.7; p = 0.88). The H. pylori eradication rate and ulcer healing rate did not differ between the groups, the latter regardless of eradication outcome.

CONCLUSIONS: Rebamipide is as effective as omeprazole in treating of H. pylori-positive gastric ulcer after eradication therapy.
Full Text
http://www.karger.com/Article/FullText/329353
DOI
10.1159/000329353
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Lee, Yong Chan(이용찬) ORCID logo https://orcid.org/0000-0001-8800-6906
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/94186
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links